Syenex的动态

We are thrilled to share that the FDA has cleared our Investigational New Drug (IND) application for UB-VV111, an in-situ generated CAR T-cell therapy for hematologic malignancies. We expect to treat our first patient by the end of year in our Phase 1 study, named INVICTA-1. UB-VV111 represents a significant advancement in off-the-shelf therapies, being the first in vivo CAR T cell therapy to be evaluated in the clinic here in the U.S. Learn more in our press release:

Professionals are showing a keen interest in investing in advanced drug therapies, with a strong focus on enhancing patient outcomes. Tune in as L.E.K. Managing Directors Alex Vadas, Adam Siebert and Jeff Holder, Ph.D. provide a comprehensive outlook on the current state and future potential of drug therapies. https://bit.ly/3W4LI3l #lifesciences #pharma #pharmaceuticals #pharmaceuticalindustry

?? We are excited to announce the 2024?BioTools Innovator?cohort featuring 20 innovative companies dedicated to revolutionizing the biotech landscape! ?? Thrilled to introduce these trailblazers to our ecosystem of partners, strategics, and industry leaders throughout our accelerator program. Check out the new tech and cutting edge solutions from our cohort companies in the official press release here?: https://lnkd.in/giF4HCi4 #iamaninnovator #biotech #techbio #bti #diagnostics #biotools #lifesciencetools